Frank Yocca - Jul 22, 2025 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)

Role
Chief Scientific Officer
Signature
/s/ Richard Steinhart, as Attorney-in-Fact for Frank Yocca, Ph.D
Stock symbol
BTAI
Transactions as of
Jul 22, 2025
Transactions value $
$0
Form type
4
Date filed
7/22/2025, 08:27 PM
Previous filing
Jun 16, 2025
Next filing
Aug 5, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Yocca Frank Chief Scientific Officer C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, 12TH FLOOR, NEW HAVEN /s/ Richard Steinhart, as Attorney-in-Fact for Frank Yocca, Ph.D 2025-07-22 0001733272

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BTAI Common Stock Award +4.38K +225.4% 6.32K Jul 22, 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Issuer previously granted the Reporting Person an award of restricted stock units that would vest based on the Issuer's satisfaction of certain performance objectives and subject to the Reporting Person's continued service with the Issuer through July 22, 2025 (the "PSUs"). On July 22, 2025, the Compensation Committee of the Issuer's Board of Directors determined that performance conditions with respect to 4,375 PSUs had been satisfied and 4,375 shares of common stock became issuable to the Reporting Person on July 22, 2025.